Global Aspergillosis Market - 2023-2030

Overview

Global Aspergillosis Market reached US$ 3.2 billion in 2022 and is expected to reach US$ 6.5 billion by 2030, growing with a CAGR of 5.6% during the forecast period 2023-2030.

Globally, the prevalence of aspergillosis is increasing as a result of the development of advanced medical practices with a rise in the proportion of immunocompromised populations due to cancer treatment, organ transplantation, and prolonged immunosuppressive therapy helps the Aspergillosis market to grow during the forecast period.

Aspergillosis is an opportunistic infection that usually affects the lower respiratory tract and is caused by inhaling spores of the filamentous fungus Aspergillus, commonly present in the environment. The spores germinate and develop into hyphae, which enter blood vessels and, with invasive disease, cause haemorrhagic necrosis and infarction. Symptoms may be those of asthma, pneumonia, sinusitis, or rapidly progressing systemic illness.

Furthermore, the global aspergillosis market is driven by various factors like a rise in research and development to introduce new and improved treatment options increasing healthcare expenditure, robust product pipeline, rise in increasing prevalence of fungal infections, rising awareness about the disease among healthcare professionals and the general population, and advancements in diagnostic techniques are primary growth drivers for the aspergillosis treatment market.

Dynamics

Rise in the Prevalence of Aspergillosis

The rise in the prevalence of aspergillosis is one of the significant key factors that help the market to grow during the forecast period. Aspergillosis affects individuals of all ages and has severe consequences, particularly in vulnerable populations. Aspergillosis is more common among individuals with weakened immune systems.

For instance, according to the University of Minnesota updated study published on the Burden of serious fungal infections in India. The annual incidence of chronic pulmonary aspergillosis is an estimated 212,502 cases, including 42,766 deaths in the year following diagnosis. About 90% of the chronic pulmonary aspergillosis burden is associated with pulmonary tuberculosis, and the authors estimate that the total prevalence is about 1.7 million cases.

Rise in Number of Ongoing Clinical Trails

The rise in ongoing clinical trials is one of the key factors that helps the market to grow during the forecast period. There are currently ongoing clinical trials which are conducted by various institutes, research industries and others. For instance, according to clinicaltrails.gov in March 2022, there was a study which is recorded titled Olorofim Aspergillus Infection Study (OASIS) where the objective of this study was to compare treatment with olorofim versus treatment with AmBisome followed by standard of care (SOC) in patients with IFD caused by proven IA or probable lower respiratory tract disease Aspergillus species (invasive aspergillosis, IA. Hence, these studies are estimated to be complete by March 2025.

Additionally, according to clinicaltrails.gov another ongoing study on Posaconazole Intravenous and Oral in Children With Invasive Aspergillosis (IA) which is conducted by Merck Sharp & Dohme LLC where the study objective is to evaluate the safety, efficacy, and pharmacokinetics of Posaconazole (POS) intravenous (IV) and oral formulations in pediatric participants 2 to <18 years of age with invasive aspergillosis (IA) and this studies are expected to complete by April 2024.

Complications Associated with Aspergillosis

Depending on the type of infection, aspergillosis can cause a variety of serious complications which act as a drawback factor that hamper the market growth during the forecast period. Some of them are Bleeding. Both aspergillomas and invasive aspergillosis can cause severe, and sometimes fatal, bleeding in your lungs. Systemic infection. The most serious complication of invasive aspergillosis is the spread of the infection to other parts of your body, especially your brain, heart and kidneys. Invasive aspergillosis spreads rapidly and may be fatal.

Segment Analysis

The global Aspergillosis market is segmented based on type, drug type, route of administration, distribution channel and region.

The Isavuconazole Segment From the Drug Type Segment Accounted For Approximately 41.7% of Aspergillosis Share

The isavuconazole segment from the drug type segment accounted for 41.7% and it is expected to be dominated during the forecast period. Isavuconazole is the newest of the clinically available advanced-generation triazole antifungals and is active against a variety of yeasts, moulds, and dimorphic fungi. Its current FDA-approved indications include the management of invasive aspergillosis as well as mucormycosis, though the latter indication is supported by limited clinical data

For instance, Basilea Pharmaceutica Ltd, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, announced that its license partner, Pfizer Inc., has received a drug approval license from the National Medical Products Administration (NMPA) in China, for the oral formulation of its antifungal Cresemba (isavuconazole) for the treatment of adult patients with invasive aspergillosis.

Geographical Penetration

North America Accounted for Approximately 38.4% of the Market Share

North America is estimated to hold about 38.4 % of the total market share throughout the forecast period, owing to the factors like FDA approvals, new product launches, rise in the healthcare infrastructure, and rising clinical trials by various institutes and research industries help this region to grow during the forecast period.

For instance, in August 2023 Astellas Pharma US, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for CRESEMBA (isavuconazonium sulfate), a prodrug of isavuconazole, an azole antifungal drug, seeking approval for the treatment of invasive aspergillosis (IA) or invasive mucormycosis (IM) in pediatric patients aged one to 17 years old. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of December 9, 2023.

Competitive Landscape

The major global players in the market include: Pfizer, Therma Fisher Scientific, Rewine Pharmaceuticals, Teva Pharmaceuticals, Eugia Pharma, krishlar Pharmaceuticals, Merck, Aozeal, Hikma, Xellia Pharmaceuticals and among others.

COVID-19 Impact Analysis

COVID-19 had a substantial impact on the global Aspergillosis market which damaged the lining of airways from severe SARS-CoV-2 infection allows Aspergillus fungi to invade the tissue, according to a recent consensus guidance from the European Confederation of Medical Mycology and the International Society for Human and Animal Mycology. These secondary fungal infections can worsen patient outcomes, and they've raised concern about emerging evidence of Aspergillus resistance to voriconazole and isavuconazole, the first-line therapies.

The coronavirus (COVID-19) pandemic also had a substantial impact on the development, production, and supply of pharmaceutical products and affected the growth of the medication used in the treatment of chronic aspergillosis such as antifungal drugs and corticosteroids manufactured by various companies across the regions such as North America, Europe, and Asia Pacific.

By Type

• Chronic Pulmonary Aspergillosis
• Allergic Bronchopulmonary Aspergillosis (ABPA)
• Invasive Aspergillosis

• Invasive Fungal Rhinosinusitis
• Invasive Pulmonary Aspergillosis

By Drug Type

• Isavuconazole
• Voriconazole
• Amphotericin-B
• Itraconazole
• Corticosteroids
• Posaconazole
• Others

By Route of Administration

• Oral
• Intravenous

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In June 2023, Endo International plc announced that its Par Sterile Products business has begun shipping posaconazole injection (18 mg/mL), the first generic version of Merck's Noxafil in the U.S., following final approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application. Posaconazole injection is indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections.
• In February 2023, Pulmatrix, Inc. a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE technology, announced the first patient dosed in a Phase 2b trial evaluating the safety and efficacy of PUR1900 in subjects with Allergic Bronchopulmonary Aspergillosis (ABPA) and asthma. PUR1900 is the company's iSPERSE-enabled dry powder formulation of itraconazole, developed for inhaled pulmonary delivery.
• In December 2022 Asahi Kasei Pharma obtained approval to manufacture and sell Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg (generic name: isavuconazonium sulfate, development) in Japan for treatment of the fungal infections of aspergillosis, mucormycosis, and cryptococcosis.

Why Purchase the Report?

• To visualize the global Aspergillosis market segmentation based on type, drug type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global Aspergillosis market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The Global Aspergillosis Market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies